Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

lio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated future financial results and product development. All forward- looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, ha
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as ā€œProteinGPS®ā€ to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat Pharma, ... 2 study evaluating the investigational oral NK-1 receptor ... with severe, chronic itch who are unresponsive or ... including topical steroids and antihistamines. ... Visual Analog Scale (VAS) itch score from baseline, ...
(Date:12/15/2014)... 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the ... independent director of the Company,s Board of Directors. ... as its CEO until its acquisition by Stanley ... transaction. Recognized as the inventor of the first Wi-Fi-based ... Wi-Fi -based RFID solutions focused on improving operational efficiency, ...
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company ... Therabron Therapeutics , Inc. The new name is derived ... structure in the lungs similar to branches on a ... protein therapeutics for the treatment of respiratory diseases. ... name to mark the company's escalation into the clinical ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Wis . - Logistics Health, Inc ., a ... has established a Web-based optimization tool to help client ... announcement, which came at the American Occupational Health ... would launch Health & Productivity Management Optimization, according to ...
... Expo for Municipal Broadband as a guest of the Graham ... with several awards for innovation and achievement in municipal government. ... a rebirth of the American municipality. , , The need ... infrastructure. , , The need to bring new business concepts ...
... Madison, Wis . - A Madison company that is ... effects of chemotherapy and radiotherapy has closed on a ... Investors of Madison. , , ProCertus BioPharm , ... begin clinical studies with cancer patients to demonstrate proof-of-concept ...
Cached Biology Technology:New Urbanism: Community planning Feng Shui 2New Urbanism: Community planning Feng Shui 3New Urbanism: Community planning Feng Shui 4New Urbanism: Community planning Feng Shui 5New Urbanism: Community planning Feng Shui 6ProCertus BioPharm secures $2.3M in financing 2ProCertus BioPharm secures $2.3M in financing 3
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Conn., May 22, 2012 /PRNewswire-iReach/ -- Global ... bird discounted registration for three significant international healthcare conferences: ... – Latin America October 29-30, ... Annual World Health Care Congress – Latin America ...
... Antibodies that help to stop the HIV virus have ... Center isolated the antibodies from immune cells called B cells ... showed that the B cells in breast milk can generate ... HIV-1 can be transmitted from mother to child via ...
... Researchers at the Hebrew University of Jerusalem have ... cells from stem cells of Fragile X patients. The ... restoration of normal gene expression in Fragile X patients. ... of inherited mental retardation, affecting hundreds of thousands of ...
Cached Biology News:Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information 2Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information 3Newly discovered breast milk antibodies help neutralize HIV 2Newly discovered breast milk antibodies help neutralize HIV 3Stem cell research paves way for progress on dealing with Fragile X retardation 2
... Storage Racks for Standard 3" Boxes. ... all makes and models of upright ... high quality stainless steel and can ... steel or plastic boxes. Custom ...
... assays utilize the membrane-permeant ester forms ... charged fluorescent beta-lactamase substrates, CCF2 and ... the cell, where cleavage by endogeneous ... their negatively charged forms, thereby trapping ...
... The ISOQUANT(R) Isoaspartate Detection Kit is ... residues in proteins and peptides, which can ... asparagine or rearrangement of aspartic acid residues ... does not depend on the monitoring of ...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Biology Products: